J&K HC Allows JMFC to Try Minor Drug Offences

In a key judgment reinforcing efficient criminal proceedings under drug regulations, the High Court of Jammu & Kashmir and Ladakh has upheld the jurisdiction of Judicial Magistrates First Class (JMFC) to try offences under the Drugs and Cosmetics Act, 1940, where the punishment does not exceed three years' imprisonment. The ruling, delivered by Justice Sanjay Dhar in M/S Aristo Laboratories Pvt. Ltd. vs. Union Territory of J&K (CRM(M) No. 509/2024), dismissed a petition by a pharmaceutical manufacturer seeking to quash ongoing trial proceedings related to a substandard injection sample. This decision clarifies that the general bar on inferior courts trying Chapter IV offences under Section 32 is not absolute, as Section 36-A specifically empowers Magistrates for summary trials in less severe cases. The case highlights procedural safeguards in drug quality enforcement while prioritizing punishment-based jurisdiction over rigid chapter classifications.

Case Background

The dispute originated in 2012 when the Drugs Officer in Anantnag, Jammu & Kashmir, lifted a sample of the injection "Monocef" (Batch No. D16B271, manufactured in February 2011, expiry July 2013) from retailer M/S M.T. Traders at Cheeni Chowk, Anantnag. The sample was analyzed by the Government Analyst in Jammu, who declared it not of standard quality on April 9, 2012. Following statutory protocol, the retailer was informed on April 17, 2012, and it disclosed procuring the drug from wholesaler M/S S.S. Traders, who in turn pointed to M/S New Ahmad Medical Agencies in Srinagar. The Srinagar agency confirmed supply from M/S Aristo Pharmaceuticals Pvt. Ltd. in Punjab, which linked back to the petitioner, M/S Aristo Laboratories Pvt. Ltd., the manufacturer in Nani Daman.

Under Section 25(2) of the Act, a portion of the sample and the test report were forwarded to the manufacturer on June 25, 2012. The company responded on July 20, 2012, asserting the drug's standard quality. After obtaining prosecution sanction from the Controller of Drug & Food Control Organization, a complaint was filed alleging offences under Section 18(a)(i) (manufacture or sale of misbranded or substandard drugs) read with Section 27(d) (punishment for such offences). Section 27(d) prescribes imprisonment up to two years and a fine of at least Rs. 20,000.

The Chief Judicial Magistrate (CJM), Anantnag, assigned the case to the District Mobile Magistrate (T), who took cognizance on December 24, 2012, and issued process against the accused, including the petitioner. In June 2013, the case was committed to the Principal Sessions Judge, Anantnag, where the petitioner sought re-testing. The sample was sent to the Central Drugs Laboratory in Kolkata, which again confirmed substandard quality. On May 30, 2015, the Sessions Judge, referencing SRO 44 dated February 6, 2006 (empowering all Judicial Magistrates in J&K under Section 36-A), transferred the case back to the CJM, Anantnag, deeming it triable by a Magistrate. A fresh cognizance order was passed on October 17, 2015. The trial proceeded, with evidence from the accused underway, until a 2022 High Court order transferred it to the CJM, Srinagar. At this advanced stage, the petitioner filed the current petition in 2024 to quash the proceedings.

The primary legal questions were: (1) Whether the CJM has jurisdiction under the Act, given Section 32's bar on courts inferior to Sessions for Chapter IV offences; (2) If the procedure under Section 23(4) for supplying a sample portion to the manufacturer was violated; and (3) Whether the cognizance orders demonstrated judicial application of mind or were merely mechanical.

Arguments Presented

The petitioner, represented by Advocate Aatir J. Kawoosa, mounted a multi-pronged challenge. First, on jurisdiction, it argued that Section 32 explicitly prohibits courts inferior to a Sessions Court from trying Chapter IV offences, which include Section 18(a)(i). The petitioner contended that this bar is absolute, rendering the CJM, Srinagar, incompetent to proceed, and sought quashing under inherent powers. Second, it alleged a fatal procedural lapse under Section 23(4), claiming no portion of the sample was supplied to the manufacturer, denying it the opportunity to contest the quality independently. This, they argued, vitiated the entire prosecution. Third, the initial cognizance order of December 24, 2012, was assailed as cryptic and non-speaking, failing to reflect any application of mind to the complaint's allegations, thus violating principles of natural justice.

In opposition, Deputy Advocate General Hakim Aman Ali defended the proceedings' validity. On jurisdiction, he emphasized that the offence under Section 27(d) carries a maximum of two years' imprisonment, falling squarely within Section 36-A's ambit for summary trials by specially empowered JMFCs. He argued that Section 36-A is a specific provision that qualifies Section 32's general restriction, especially since Section 36-AB limits special courts to graver offences like adulterated or spurious drugs. The DAG highlighted the Principal Sessions Judge's 2015 order correctly applying SRO 44, empowering state Magistrates. Factually, he pointed to the complaint's averment that the sample was sent on June 25, 2012, eliciting the petitioner's detailed response and request for re-testing—evidence of compliance. The re-test by the Central Lab reaffirmed substandard quality, underscoring the prosecution's merits. Finally, on cognizance, he noted the fresh October 17, 2015, order by the CJM, Anantnag, which explicitly reviewed allegations and found prima facie offences, curing any initial defect.

Both sides delved into the Act's scheme: the petitioner stressed chapter-based exclusivity to protect manufacturers from lower court overreach, while the respondent highlighted legislative intent for expedited handling of minor offences to safeguard public health without overwhelming higher courts.

Legal Analysis

Justice Sanjay Dhar's judgment methodically dissects the contentions through statutory interpretation, prioritizing harmony within the Drugs and Cosmetics Act. At the outset, the court analyzed Sections 27(d), 32, 36-A, and 36-AB. Section 27(d) prescribes punishment for substandard drugs—imprisonment up to two years—placing it below the three-year threshold in Section 36-A. This section mandates summary trials by empowered JMFCs for such offences, explicitly excepting only serious violations under Section 36-AB (e.g., adulteration under Sections 13, 22, or 27(a)/(c)). The court underscored that Section 32's bar on inferior courts for Chapter IV applies only "except otherwise provided" in the Act. Here, Section 36-A provides otherwise, making punishment the decisive factor rather than mere chapter placement. Justice Dhar observed that classifying jurisdiction by chapter alone would render Section 36-A otiose, defeating the legislature's aim for efficient adjudication of less culpable offences.

This reasoning draws no direct precedents but aligns with principles of statutory construction where specific provisions prevail over general ones (as per the saving clause in Section 32(2)). The court referenced the Principal Sessions Judge's May 30, 2015, order, which invoked SRO 44 of 2006 to empower J&K Magistrates under Section 36-A, affirming the transfer's propriety. By emphasizing punishment over chapter, the ruling distinguishes minor substandard drug cases (like this one) from severe ones warranting Sessions or special courts, promoting workload balance in the judiciary.

On the sample supply, the court rejected the petitioner's claim as factually baseless. The complaint explicitly stated dispatch on June 25, 2012, and the petitioner's July 20, 2012, response—denying defects and seeking re-analysis—belied any non-receipt. The subsequent re-test request and the Central Lab's confirmatory report further evidenced compliance with Section 23(4), which ensures manufacturers' rights without halting enforcement. Justice Dhar clarified that procedural violations must be substantive, not hyper-technical, especially when the accused actively engaged.

Regarding cognizance, the court differentiated the initial December 2012 order (from the Mobile Magistrate, potentially non-speaking) from the fresh October 2015 order by the CJM, Anantnag. The latter, post-transfer, applied mind to allegations, prima facie establishing Section 18(a)(i) offences, and issued process accordingly. This cured any defect, as subsequent judicial scrutiny validates proceedings at advanced stages. The analysis reinforces that quashing under Section 482 CrPC (implicit in the petition) is exceptional, not for curable irregularities.

Overall, the judgment integrates the Act's dual goals: stringent drug quality control for public safety and procedural fairness, without allowing dilatory tactics in routine cases.

Key Observations

The court's pivotal excerpts illuminate its reasoning:

1. On jurisdiction: "Thus, if an offence, which is punishable with imprisonment for a term not exceeding three years, the same would be triable by a Judicial Magistrate of first class specially empowered by the Government in this behalf in spite of the fact that the said offence may fall within Chapter-IV of the Act." (Para 13)

2. Emphasizing statutory priority: "Section 36-A of the Act provides for summary trial of certain types of offences, which are punishable with imprisonment for a term not exceeding three years, by a Judicial Magistrate of first class specially empowered... The saving clause in sub-section (2) of Section 32 of the Act clearly provides that the said sub-section would not apply to a case where the Act provides otherwise." (Para 13)

3. On sample compliance: "The contention of the petitioner that portion of the sample was not furnished to it is factually incorrect in view of clear stand of the petitioner in response to communication dated 25.06.2012 issued by the Drugs Inspector." (Para 16)

4. Regarding cognizance: "In the said order, the learned Magistrate has, after noticing the allegations made in the complaint and applying his mind to the same, recorded that prima facie offences under Section 18(a)(i) of the Act are made out against the accused, whereafter the process has been issued against them." (Para 18)

5. Affirming Sessions Judge's view: "In fact, the aforesaid aspect of the matter has been dealt with by the learned Principal Sessions Judge, Anantnag, while passing order dated 30.05.2015, by making reference to SRO 44 of 2006, which empowers all the Judicial Magistrates of the State to try the offences in exercise of powers under Section 36-A of the Act." (Para 14)

These observations underscore the court's fact-driven, provision-centric approach.

Court's Decision

The High Court found no merit in the petition and dismissed it in its entirety on November 14, 2025, vacating any interim relief. Justice Dhar explicitly rejected all grounds, holding the CJM, Srinagar, competent to proceed with the trial under Section 36-A.

The practical effects are manifold. For the ongoing case, it allows completion of evidence and potential conviction, reinforcing manufacturer accountability in supply chains for substandard drugs—a persistent public health concern in India. Broader implications include streamlined prosecutions: minor offences (up to three years) now firmly within Magistrates' purview, reducing Sessions Court burdens and expediting resolutions. This could enhance regulatory efficiency, enabling Drugs Inspectors to focus on enforcement without jurisdictional hurdles.

For future cases, the ruling sets a precedent in J&K and potentially beyond, clarifying that Section 32's bar yields to Section 36-A's specifics. Pharmaceutical entities must anticipate Magistrate trials for non-grievous violations, emphasizing robust quality controls and prompt responses to sampling. It also validates re-testing protocols, as seen here, while cautioning against baseless procedural challenges at late stages.

In the justice system, this promotes access and speed, aligning with CrPC goals under summary procedures. For legal practitioners, it highlights the need to scrutinize punishment quanta early and document procedural steps meticulously. Ultimately, by balancing due process with public interest, the decision bolsters the Act's role in preventing substandard drugs from reaching consumers, potentially averting health risks in regions like J&K where medical supply chains are critical.